Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Lymphoma
•
Myeloma
•
General Internal Medicine
•
Hematology
What would your next line of therapy be for a young patient with Waldenstrom's Macroglobulinemia (MYD88 and CXCR wild type) with hyperviscosity who did not have a response to Bendamustine/Rituximab?
Related Questions
How would you manage LPL with associated AL amyloidosis?
In a patient with history of recurrent VTE despite anticoagulation, would you consider lenalidomide as part of your initial myeloma regimen?
How do you approach second-line options for relapsed myeloma after front-line quadruplet therapy?
For patients diagnosed with T-cell lymphoblastic lymphoma with CNS involvement (CSF), what is your approach to the typical schedule for IT chemotherapy?
Would you consider daratumumab monotherapy as standard of care for smoldering multiple myeloma based on the AQUILA trial?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
How would you approach management and monitoring of AL amyloidosis with isolated renal involvement?
How would you manage a patient with p53 mutated MCL who has progressed after a BTKi and CAR-T with a CD20 negative clone?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
